TNDM insider buying and SEC filings, explained
Tandem Diabetes Care Inc. · CIK 1438133
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$37K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 27, 2026 | Planned (10b5-1) | Christopher J. Twomey (Director) sold 1,700 shares at $19.15 ($33K), marked as a 10b5-1 plan trade. Holdings down 7% to 24,434 shares. | SEC filing Filed Oct 29, 2026, 4:06 PM ET |
| Mar 17, 2026 | Planned (10b5-1) | Mark David Novara (EVP & Chief Commercial Officer) sold 187 shares at $23.05 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 37,656 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Mark David Novara (EVP & Chief Commercial Officer) sold 2 shares at $22.81 ($46), marked as a 10b5-1 plan trade. Holdings down <1% to 35,969 shares. | SEC filing Filed Mar 9, 2026 |
57 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TNDM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.